Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
PII-035
A BIOEQUIVALENCE AND FOOD EFFECT CLINICAL STUDY OF ZOLIFLODACIN, FIRST-IN-CLASS ORAL ANTIBIOTIC, BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA
Favorite
PII-210
A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.
Favorite
PII-041
A CHEMICAL BIOLOGY STRATEGY FOR PREDICTING OATP1B-TYPE TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) LIABILITIES
Favorite
TIP-001
A CLINICAL STUDY OF NOVEL BCRP AND ESTABLISHED OATP BIOMARKERS FOR PREDICTING DRUG-DRUG INTERACTIONS.
Favorite
PII-179
A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES.
Favorite
LB-001
A GENERIC TACROLIMUS CAPSULE SHOWN NOT TO BE BIOEQUIVALENT TO THE BRAND TACROLIMUS CAPSULE IN A POST-APPROVAL PHARMACOKINETIC BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS
Favorite
PT-006
A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.
Favorite
OAII-003
A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Favorite
PT-003
A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Favorite
LB-002
A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC (MPBPK) MODEL TO CHARACTERIZE PSA07 BACTERIOPHAGE (PHAGE) PHARMACOKINETICS (PK) FOLLOWING INTRAVENOUS (IV) ADMINISTRATION IN MICE FOR TREATMENT OF P. AERUGINOSA (PSA) INFECTIONS
Favorite
PII-005
A NOVEL ENDOTYPE OF ADULT ASTHMA SUGGESTED BY PLASMA METABOLITE PROFILING OF THE COHORT FOR REALITY AND EVOLUTION OF ADULT ASTHMA IN KOREA (COREA)
Favorite
LB-003
A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA).
Favorite
LB-004
A NOVEL PHYSIOLOGICALLY BASED OCULAR PHARMACOKINETIC MODEL INCORPORATING ACCURATE DYNAMICS OF THE ANTERIOR EYE
Favorite
PII-090
A PHARMACOKINETIC AND ENZYME TURNOVER MODEL PREDICTS MAJOR ROLES FOR CYP2B6 GENOTYPES ON THE MAGNITUDE OF EFAVIREZ AUTOINDUCTION OF METABOLISM AND CLEARNCE IN HEALTHY VOLUNTEERS
Favorite
LB-005
A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMX0035 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Favorite
PII-091
A PHASE 1 OPEN-LABEL, FIXED-SEQUENCE 3-PERIOD STUDY TO EVALUATE PHARMACOKINETIC INTERACTIONS BETWEEN FIMASARTAN AND INDAPAMIDE IN HEALTHY VOLUNTEERS
Favorite
PII-092
A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Favorite
PII-194
A PHASE 1 STUDY COMPARING PHARMACOKINETICS OF RIMEGEPANT 25 MG ORALLY DISINTEGRATING TABLET (ODT) PEDIATRIC FORMULATION WITH RIMEGEPANT 75 MG ODT ADULT FORMULATION, WHEN ADMINISTERED AT A SINGLE DOSE OF 75 MG UNDER FASTING CONDITIONS
Favorite
PII-195
A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.
Favorite
PII-196
A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.
Favorite
PII-093
A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS.
Favorite
PII-094
A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Favorite
PII-095
A POPULATION PHARMACOKINETIC (PK) MODEL OF MILVEXIAN, A SMALL MOLECULE FACTOR XIA INHIBITOR, IN HEALTHY VOLUNTEERS.
Favorite
PII-185
A QUANTITATIVE MODELING APPROACH TO PREDICT AVAILABILITY OF GENERIC ORPHAN DRUG PRODUCTS.
Favorite
PII-211
A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PRECLINICAL TO CLINICAL TRANSLATION OF ANTIBODY-DRUG CONJUGATE (ADC) EFFICACY AND THROMBOCYTOPENIA.
Favorite
PII-212
A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS
Favorite
PII-006
A SNAPSHOT OF PHARMACODYNAMIC BIOMARKERS BIOANALYSIS IN 16 BLAS APPROVED FOR NEUROLOGY INDICATIONS.
Favorite
PII-186
A SURVEY ON RECOMMENDATION OF FOOD CONDITIONS IN BIOEQUIVALENCE STUDIES WITH PHARMACOKINETIC ENDPOINTS FOR GENERIC ORAL ANTINEOPLASTIC DRUG DEVELOPMENT.
Favorite
PWI-002
A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Favorite
PII-096
A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Favorite
PII-072
A VALUE PROPOSITION FOR USING PHARMACOGENETIC TESTING IN MENTAL HEALTH CARE
Favorite
PII-045
ACETYLATION-DEPENDENT REGULATION OF NUCLEAR PD-L1 IS CRITICAL TO SISTER CHROMATID COHESION IN TRIPLE NEGATIVE BREAST CANCER
Favorite
CT-009
ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
PII-073
ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
CT-001
AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Favorite
PII-160
AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Favorite
PT-010
ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
OAII-002
ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
PII-046
AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS
Favorite
PII-097
AN INTEGRATED ASSESSMENT OF THE AME PROPERTIES OF SELTOREXANT UTILIZING PRECLINICAL IN VITRO, IN VIVO, AND HUMAN ADME DATA.
Favorite
PII-047
AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE
Favorite
PII-043
ANTIDEPRESSANT EXPOSURE IN THE ADOLESCENT BRAIN: FLUOXETINE AND PHARMACOGENETIC INFLUENCES ON BRAIN DISPOSITION
Favorite
PII-048
APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.
Favorite
AI-001
APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Favorite
PII-098
APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Favorite
AI-002
APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Favorite
PT-007
APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Favorite
CT-006
APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Favorite
PII-161
APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Favorite
PII-162
APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Favorite
CT-007
APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Favorite
PII-163
APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO SUPPORT BIOEQUIVALENCE EVALUATION OF MESALAMINE DELAYED RELEASE TABLETS
Favorite
PII-001
APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT
Favorite
LB-006
ARTERIAL STIFFNESS AND SYSTEMIC VASCULAR CORRELATES OF BRAIN AMYLOIDOSIS AND PRECLINICAL AD
Favorite
PII-025
ASCENDING DOSE IN VIVO QT STUDIES HAVE THE SENSITIVITY TO DETECT QT INTERVAL CHANGES THAT ARE SUFFICIENT TO SUPPORT A CLINICAL QT WAIVER: ASSESSMENT OF QT/QTC INTERVAL CHANGES USING AN ESCALATING DOSE DESIGN IN TELEMETERED BEAGLE DOGS.
Favorite
PII-164
ASSESSING CYTOCHROME P450 DRUG INTERACTION RISK FOR ONC201 USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Favorite
LB-007
ASSESSING POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING Δ-9-TETRAHYDROCANNABINOL AND CANNABIDIOL IN HEALTHY ADULTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS
Favorite
PII-187
ASSESSMENT OF MALE INFERTILITY RISKS TO SUPPORT PRODUCT-SPECIFIC GUIDANCE DEVELOPMENT FOR GENERIC ORAL PRODUCTS.
Favorite
PII-165
AUTOMATED QUALIFICATION FRAMEWORK FOR PHYSIOLOGICALLY-BASED QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING
Favorite
PII-099
AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE: JOINT LONGITUDINAL-SURVIVAL DISEASE PROGRESSION MODELS.
Favorite
